Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Kristopher A. Knight"'
Autor:
Scott A. Becker, Brian G. Petrich, Bing Yu, Kristopher A. Knight, Harrison C. Brown, Sunil S. Raikar, Christopher B. Doering, H. Trent Spencer
Publikováno v:
Molecular Therapy: Oncolytics, Vol 29, Iss , Pp 145-157 (2023)
Adoptive cell therapy (ACT) utilizing γδ T cells is becoming a promising option for the treatment of cancer, because it offers an off-the-shelf allogeneic product that is safe, potent, and clinically effective. Approaches to engineer or enhance imm
Externí odkaz:
https://doaj.org/article/53f3291d08774bab9a7136bad26a24d2
Autor:
Kiran K. Parwani, Gianna M. Branella, Rebecca E. Burnham, Andre J. Burnham, Austre Y. Schiaffino Bustamante, Elisabetta Manuela Foppiani, Kristopher A. Knight, Brian G. Petrich, Edwin M. Horwitz, Christopher B. Doering, H. Trent Spencer
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Vγ9Vδ2 T cells represent a promising cancer therapy platform because the implementation of allogenic, off-the-shelf product candidates is possible. However, intravenous administration of human Vγ9Vδ2 T cells manufactured under good manufacturing
Externí odkaz:
https://doaj.org/article/f3f5f8f350124206a8b21fc88a9f4d24
Autor:
Athena L. Russell, Chengyu Prince, Taran S. Lundgren, Kristopher A. Knight, Gabriela Denning, Jordan S. Alexander, Jaquelyn T. Zoine, H. Trent Spencer, Shanmuganathan Chandrakasan, Christopher B. Doering
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 21, Iss , Pp 710-727 (2021)
Hematopoietic stem and progenitor cell (HSPC) lentiviral gene therapy is a promising strategy toward a lifelong cure for hemophilia A (HA). The primary risks associated with this approach center on the requirement for pre-transplantation conditioning
Externí odkaz:
https://doaj.org/article/b389bd2ba16049b3ab15cefbbc027227
Autor:
Jaquelyn T. Zoine, Kristopher A. Knight, Lauren C. Fleischer, Kathryn S. Sutton, Kelly C. Goldsmith, Christopher B. Doering, H. Trent Spencer
Publikováno v:
OncoImmunology, Vol 8, Iss 8 (2019)
An effective therapy regimen for relapsed/refractory high-risk neuroblastoma (NB) includes the anti-GD2 monoclonal antibody, dinutuximab, in combination with temozolomide and irinotecan, supporting a role for chemo-immunotherapy in NB. γδ T cells a
Externí odkaz:
https://doaj.org/article/c49d9607fe3b4710974be40de0fcdfb1
Autor:
Sunil S. Raikar, Lauren C. Fleischer, Robert Moot, Andrew Fedanov, Na Yoon Paik, Kristopher A. Knight, Christopher B. Doering, H. Trent Spencer
Publikováno v:
OncoImmunology, Vol 7, Iss 3 (2018)
Relapsed T-cell malignancies have poor outcomes when treated with chemotherapy, but survival after allogeneic bone marrow transplantation (BMT) approaches 50%. A limitation to BMT is the difficulty of achieving remission prior to transplant. Chimeric
Externí odkaz:
https://doaj.org/article/595175915e694c6f9cbda7b8ad257be9
Autor:
Fania Szlam, Christopher W. Coyle, Ernest T. Parker, Gabriela Denning, Roman M. Sniecinski, Eric A. Gaucher, Christopher B. Doering, H. Trent Spencer, Chen Michelle H, Jordan M. Shields, Kristopher A. Knight, Anatolii Purchel, Andrew Fedanov, Caelan E. Radford, Pete Lollar
Publikováno v:
Blood Adv
Orthologous proteins contain sequence disparity guided by natural selection. In certain cases, species-specific protein functionality predicts pharmacological enhancement, such as greater specific activity or stability. However, immunological barrier
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6bfce55878e87a2640a3d2cba6be06c
https://doi.org/10.1182/bloodadvances.2021004742
https://doi.org/10.1182/bloodadvances.2021004742
Autor:
Jordan S. Alexander, Athena Liza Russell, Kristopher A. Knight, Jaquelyn T. Zoine, Gabriela Denning, Chengyu Prince, Christopher B. Doering, Taran S. Lundgren, H. Trent Spencer, Shanmuganathan Chandrakasan
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 21, Iss, Pp 710-727 (2021)
Molecular Therapy: Methods & Clinical Development, Vol 21, Iss, Pp 710-727 (2021)
Hematopoietic stem and progenitor cell (HSPC) lentiviral gene therapy is a promising strategy toward a lifelong cure for hemophilia A (HA). The primary risks associated with this approach center on the requirement for pre-transplantation conditioning
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51cb314a406f4239e729f4eb6dc60ca6
https://doi.org/10.1016/j.omtm.2021.04.016
https://doi.org/10.1016/j.omtm.2021.04.016
Autor:
Kelly C. Goldsmith, Christopher B. Doering, Jaquelyn T. Zoine, Kristopher A. Knight, Lauren C. Fleischer, Kathryn S. Sutton, H. Trent Spencer
Publikováno v:
Oncoimmunology
OncoImmunology, Vol 8, Iss 8 (2019)
OncoImmunology, Vol 8, Iss 8 (2019)
An effective therapy regimen for relapsed/refractory high-risk neuroblastoma (NB) includes the anti-GD2 monoclonal antibody, dinutuximab, in combination with temozolomide and irinotecan, supporting a role for chemo-immunotherapy in NB. γδ T cells a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42b2def2c42c046f5718af875f48f3c2
http://europepmc.org/articles/PMC6682349
http://europepmc.org/articles/PMC6682349
Autor:
Lauren C. Fleischer, Robert Moot, Na Yoon Paik, Christopher B. Doering, Andrew Fedanov, H. Trent Spencer, Kristopher A. Knight, Sunil S. Raikar
Publikováno v:
OncoImmunology, Vol 7, Iss 3 (2018)
Relapsed T-cell malignancies have poor outcomes when treated with chemotherapy, but survival after allogeneic bone marrow transplantation (BMT) approaches 50%. A limitation to BMT is the difficulty of achieving remission prior to transplant. Chimeric
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01140c13667129abcedda55f4c9b58f0
https://doaj.org/article/595175915e694c6f9cbda7b8ad257be9
https://doaj.org/article/595175915e694c6f9cbda7b8ad257be9
Autor:
Philip M. Zakas, Kristopher A. Knight, Christopher B. Doering, Harrison C. Brown, H. Trent Spencer, Eric A. Gaucher, Shannon L. Meeks
Publikováno v:
Nature biotechnology
Optimization of a protein’s pharmaceutical properties is usually carried out by rational design and/or directed evolution. Here we test an alternative approach based on ancestral sequence reconstruction. Using available genomic sequence data on coa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7445e218e0926946ad9a9c0f6ea7383f
https://pubmed.ncbi.nlm.nih.gov/27669166
https://pubmed.ncbi.nlm.nih.gov/27669166